Glaucoma News

Enrollment is complete in a phase 2 clinical trial of NCX 470, Nicox’s second-generation nitric oxide-donating bimatoprost analog, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release.

The FDA has accepted a new drug application for Bimatoprost Sustained-Release to reduce IOP in primary open-angle glaucoma or ocular hypertension, Allergan announced.

iSTAR Medical’s MINIject device showed positive results in a first-in-human trial, with a mean pressure reduction of 15 mm Hg at 18 months, according to a press release.

Guardion Health Sciences Inc. announced the launch of GlaucoCetin, a propriety formula shown in a clinical trial to reverse mitochondrial dysfunction in the optic nerve cells of glaucoma patients.

Aerie Pharmaceuticals has completed enrollment in a phase 2 clinical trial of netarsudil ophthalmic solution in Japan, according to a press release.

NEWPORT BEACH, Calif. — At OCTANe’s Ophthalmology Technology Summit, Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses the company’s latest products for glaucoma and retinal diseases as well as the construction of a manufacturing facility in Ireland.

ST. LOUIS – Jim Fanelli, OD, FAAO, said here at Optometry’s Meeting that he uses OCT in his practice for patients who have macular disease and glaucoma.

The Xen gel stent showed similar safety and efficacy in a study involving patients with pseudoexfoliative glaucoma and primary open angle glaucoma as both a standalone procedure and when combined with cataract surgery.

A study published in the British Journal of Ophthalmology concluded that patients with newly diagnosed primary open-angle glaucoma scored marginally better on an illness perception questionnaire on items relating to impact on life in general, experience of symptoms and understanding of their condition than those diagnosed more than 2 years ago.

The fluctuation of diastolic blood pressure, diurnal IOP and the presence of a disc hemorrhage are significantly associated with progression of the disease in patients with normal tension glaucoma, according to the study published in the British Journal of Ophthalmology.